Featured Stock: Array BioPharma Inc. (NASDAQ:ARRY)

earnings estimates

Array BioPharma Inc. (NASDAQ:ARRY)

Wells Fargo Maintains Array BioPharma Inc. (NASDAQ:ARRY)’s stock to Outperform with the price target of $33. This rating was issued on 6/28/18. The stock recently closed its previous session at $13.12 by showing a percentage change of 1.55% from its previous day closing price of $12.92.

Price Target is basically a projection of future price of a company’s stock by the expert analysis of investment analysts or investment firms. There may be various price targets for a stock. These analysts and investment firms use various valuation methods to decide a price target for a stock.

Several investment firms issued their expert ratings on Array BioPharma Inc. (NASDAQ:ARRY) in which Cantor Fitzgerald Maintains Array BioPharma Inc. (NASDAQ:ARRY) to Overweight by settling a price target of $26 on 6/25/18. Leerink Swann Maintains the stock to Outperform on 2/07/18 by stationing a price target of $20. Stifel Nicolaus Maintains the company’s stock to Buy on 2/07/18 by setting a price target of $23. Leerink Swann Upgrades Array BioPharma Inc. (NASDAQ:ARRY) to Outperform with no specific Price Target.

Array BioPharma Inc. (NASDAQ:ARRY) currently has a consensus Price Target of $24.63. While some analysts have a High Price target for the stock of $33 and a Low Price Target of $18.

Several sell side analysts reviewed their recommendations on Array BioPharma Inc. (NASDAQ:ARRY) where 4 analyst have rated the stock as Strong Buy, 4 analysts said it’s a Buy, 0 rated the stock as Hold, 0 analysts reported Underperform and 0 analysts gave their recommendations as Sell. (Current Month Yahoo Finance Ratings)

Zacks Investment Research also rated the stock with a value of 1. This scale runs from 1 to 5 where 1 represents Strong Buy and 5 represents Sell.

In the last Quarter, Array BioPharma Inc. (NASDAQ:ARRY) reported its Actual EPS of $-0.25/share. The analysts offering Earnings Estimates for the company were believing that Array BioPharma Inc. (NASDAQ:ARRY) could bring EPS of $-0.24/share. The difference between Actual EPS and Estimated EPS was -0.01 Percent. Thus the company showed an Earnings Surprise of -4.2 Percent.

Array BioPharma Inc. (NASDAQ:ARRY) has a market capitalization of 2.79 Billion. The stock traded with the volume of 2.56 Million shares in the last trading session. The stock touched its high share price of $20.21 on 06/21/18 and the stock also touched its Lowest price in the last 52-weeks of trading on 10/27/17 as $9.98. The company has a 1 Year high price target of $24.63. The stock is currently trading with a distance of 20-Day Simple Moving Average (SMA20) of -9.69%. The Moving Average SMA50 is -10.13% while SMA200 is -16.07%.

Array BioPharma Inc. (NASDAQ:ARRY) is currently showing its ROA (Return on Assets) of -30.7%. The Return on Investment (ROI) is at -41.8% while it’s Return on Equity (ROE) value stands at -61.8%. The stock currently shows its YTD (Year to Date) performance of 2.5 percent while its Weekly performance value is -12.88%. The Monthly and Yearly performances are -5.27 percent and 6.75 percent respectively. The Relative Volume value measured for Array BioPharma Inc. (NASDAQ:ARRY) is 1.17. The Average Volume (3 months) is 2.18 Million.

The stock currently has its Annual Dividend of $0 and an annual Dividend Yield of 0 Percent. ARRY has P/E (Price to Earnings ttm) value of 0, Forward P/E of 0, P/C (Price to cash per share) of 7.3 and Price to Free Cash Flow (P/FCF) value of 0. The stock is showing its Operating Margin of -78.5 percent.

Company Profile:

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases. The company’s proprietary drug development pipeline is focused on the treatment of cancer and inflammatory disease and includes clinical candidates that are designed to regulate therapeutically important targets. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas.